1 | 1 | | 1 of 1 |
---|
2 | 2 | | HOUSE DOCKET, NO. 1476 FILED ON: 1/15/2025 |
---|
3 | 3 | | HOUSE . . . . . . . . . . . . . . . No. 2472 |
---|
4 | 4 | | The Commonwealth of Massachusetts |
---|
5 | 5 | | _________________ |
---|
6 | 6 | | PRESENTED BY: |
---|
7 | 7 | | Kathleen R. LaNatra |
---|
8 | 8 | | _________________ |
---|
9 | 9 | | To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General |
---|
10 | 10 | | Court assembled: |
---|
11 | 11 | | The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill: |
---|
12 | 12 | | An Act protecting patient safety regarding non-FDA approved drugs. |
---|
13 | 13 | | _______________ |
---|
14 | 14 | | PETITION OF: |
---|
15 | 15 | | NAME:DISTRICT/ADDRESS :DATE ADDED:Kathleen R. LaNatra12th Plymouth1/15/2025Patrick Joseph Kearney4th Plymouth2/3/2025 1 of 4 |
---|
16 | 16 | | HOUSE DOCKET, NO. 1476 FILED ON: 1/15/2025 |
---|
17 | 17 | | HOUSE . . . . . . . . . . . . . . . No. 2472 |
---|
18 | 18 | | By Representative LaNatra of Kingston, a petition (accompanied by bill, House, No. 2472) of |
---|
19 | 19 | | Kathleen R. LaNatra and Patrick Joseph Kearney relative to the distribution of compounded |
---|
20 | 20 | | medications. Public Health. |
---|
21 | 21 | | The Commonwealth of Massachusetts |
---|
22 | 22 | | _______________ |
---|
23 | 23 | | In the One Hundred and Ninety-Fourth General Court |
---|
24 | 24 | | (2025-2026) |
---|
25 | 25 | | _______________ |
---|
26 | 26 | | An Act protecting patient safety regarding non-FDA approved drugs. |
---|
27 | 27 | | Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority |
---|
28 | 28 | | of the same, as follows: |
---|
29 | 29 | | 1 Section 1. As used in this section, the following words shall have the following |
---|
30 | 30 | | 2meanings: |
---|
31 | 31 | | 3 a) "Compounded Medication" means a medication that is prepared, mixed, assembled, |
---|
32 | 32 | | 4altered, or otherwise modified by a licensed pharmacist to meet the unique needs of an individual |
---|
33 | 33 | | 5patient pursuant to a prescription. |
---|
34 | 34 | | 6 b) "Retail Pharmacy" means any establishment, including a community pharmacy, |
---|
35 | 35 | | 7licensed by the state to dispense prescription medications directly to patients. |
---|
36 | 36 | | 8 c) "Resale" means selling, distributing, or otherwise transferring a medication that a retail |
---|
37 | 37 | | 9pharmacy has purchased, in any quantity, to another entity or individual who is not the patient |
---|
38 | 38 | | 10for whom the medication was originally compounded. |
---|
39 | 39 | | 11 Section 2. 2 of 4 |
---|
40 | 40 | | 12 In order to ensure the safe and ethical distribution of compounded medications: |
---|
41 | 41 | | 13 (a) No retail pharmacy shall resell compounded medications. |
---|
42 | 42 | | 14 (b) Compounded medications prepared by a retail pharmacy shall be dispensed only to |
---|
43 | 43 | | 15the patient for whom the medication was originally compounded, pursuant to a valid |
---|
44 | 44 | | 16prescription. |
---|
45 | 45 | | 17 (c) Any violation of this section shall subject the retail pharmacy to disciplinary actions |
---|
46 | 46 | | 18as determined by the state's Board of Registration in Pharmacy, including but not limited to |
---|
47 | 47 | | 19fines, suspension, or revocation of the pharmacy's license. |
---|
48 | 48 | | 20 Section 3. |
---|
49 | 49 | | 21 (1) The resale of a compounded drug that is labeled “not for resale” in accordance with |
---|
50 | 50 | | 22section (2)(c)(ix) is prohibited. |
---|
51 | 51 | | 23 (2) The label of any drug compounded or repackaged by an outsourcing facility shall |
---|
52 | 52 | | 24include, but not be limited to the following: |
---|
53 | 53 | | 25 (a) a statement that the compounded drug is a compounded drug or a reasonable |
---|
54 | 54 | | 26comparable alternative statement that prominently identifies the drug as a compounded drug; |
---|
55 | 55 | | 27 (b) the name, address, and phone number of the applicable outsourcing facility; and |
---|
56 | 56 | | 28 (c) with respect to the compounded drug: |
---|
57 | 57 | | 29 (i) the lot or batch number; |
---|
58 | 58 | | 30 (ii) the established name of the drug; 3 of 4 |
---|
59 | 59 | | 31 (iii) the dosage form and strength; |
---|
60 | 60 | | 32 (iv) the statement of quantity or volume, as appropriate; |
---|
61 | 61 | | 33 (v) the date that the drug was compounded; |
---|
62 | 62 | | 34 (vi) the expiration date; |
---|
63 | 63 | | 35 (vii) storage and handling instructions; |
---|
64 | 64 | | 36 (viii) the NDC number, if available; |
---|
65 | 65 | | 37 (ix) the statement that the drug is not for resale, and if the drug product is distributed by |
---|
66 | 66 | | 38an outsourcing facility other than pursuant to a prescription for an individual identified patient, |
---|
67 | 67 | | 39the statement “office use only”; |
---|
68 | 68 | | 40 (x) a list of the active and inactive ingredients, identified by established name, and the |
---|
69 | 69 | | 41quantity or proportion of each ingredient. |
---|
70 | 70 | | 42 (3) The container from which the individual units of the compounded drug are removed |
---|
71 | 71 | | 43for dispensing or for administration (such as a plastic bag containing individual product syringes) |
---|
72 | 72 | | 44shall include-- (a) a list of active and inactive ingredients, identified by established name, and the |
---|
73 | 73 | | 45quantity or proportion of each ingredient; (b) the following information to facilitate adverse |
---|
74 | 74 | | 46event reporting: www.fda.gov/medwatch and 1-800-FDA-1088 (or any successor Internet Web |
---|
75 | 75 | | 47site or phone number); and (c) directions for use, including, as appropriate, dosage and |
---|
76 | 76 | | 48administration. |
---|
77 | 77 | | 49 (4) No compounded or repackaged drug will be sold or transferred by any entity other |
---|
78 | 78 | | 50than the outsourcing facility that compounded or repackaged such drug. This does not prohibit 4 of 4 |
---|
79 | 79 | | 51the administration of a drug in a health care setting or an outsourcing facility dispensing a drug |
---|
80 | 80 | | 52pursuant to a properly executed prescription. |
---|
81 | 81 | | 53 (5) A compounded drug labeled “office use only” in accordance with section (2)(c)(ix) |
---|
82 | 82 | | 54shall be administered in the office and not dispensed to the patient. |
---|
83 | 83 | | 55 Section 4. Enforcement |
---|
84 | 84 | | 56 (a) The state's Board of Registration in Pharmacyshall have the power to enforce the |
---|
85 | 85 | | 57provisions of this Act. |
---|
86 | 86 | | 58 (b) The regulatory authority is authorized to promulgate rules and regulations necessary |
---|
87 | 87 | | 59for the implementation and enforcement of this Act. |
---|
88 | 88 | | 60 Section 5. Severability |
---|
89 | 89 | | 61 If any provision of this Act, or the application thereof to any person or circumstance, is |
---|
90 | 90 | | 62held invalid, the remainder of the Act and the application of such provision to other persons or |
---|
91 | 91 | | 63circumstances shall not be affected thereby. |
---|